Search results
Results from the WOW.Com Content Network
Now, approved for weight loss under the name Zepbound, the drug is available in six doses—2.5, 5, 7.5, 10, 12.5, and 15 milligrams, according to Eli Lilly, which makes the injectable medication ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Cetuximab target the epidermal growth factor receptor . It is approved for use in the treatment of metastatic colorectal cancer [24] [25] and squamous cell carcinoma of the head and neck. [26] [27] Panitumumab also targets the EGFR. It is approved for the use in the treatment of metastatic colorectal cancer. Bevacizumab targets circulating VEGF ...
Following a first investigational new drug application in 1989 and biologics license application in 2000, Bexxar was approved by the FDA in 2003. [10] [8] Sale of Bexxar was discontinued and marketing approval was withdrawn in February 2014 due to a decline in usage (fewer than 75 patients in 2012).
This is a complete list of androgens/anabolic steroids (AAS) and formulations that are approved by the FDA Tooltip Food and Drug Administration and available in the United States. AAS like testosterone are used in androgen replacement therapy (ART), a form of hormone replacement therapy (HRT), and for other indications.
Both Ozempic, made by Novo Nordisk, and Mounjaro, made by Eli Lilly, are FDA-approved to treat Type 2 diabetes, but some doctors prescribe the medication "off-label" for weight loss, as is ...
The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA. [4] In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer. [5] On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale. [5]
It is first FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain. [15] In June 2019, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the agent for the treatment of adult and pediatric patients with NTRK fusion–positive, advanced recurrent solid tumors ...